Moclobemide (Ro 11-1163) in long-term treatment.
Patients requiring long-term treatment of depression (at least 60 days) were followed up at monthly intervals under treatment with moclobemide. A total of 102 patients completed 1 year of treatment; the mean dose at the start of treatment was 340 mg daily, decreasing to 300 mg after a year. Three quarters of these patients were suffering from endogenous depression. The investigator's overall assessment of efficacy was good or very good for 96% of patients; efficacy judged together with tolerance was good or very good for 85% of patients. There were no noteworthy changes in safety parameters throughout the study, and adverse events were mainly minor and of short duration. The result of this analysis suggests that moclobemide is effective, safe and well tolerated in long-term administration.
Stefanis
C N
CN
Department of Psychiatry, University of Athens, Eginition Hospital, Greece.
Merz-Frei
K
K
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000928:Antidepressive Agents / Q000008:administration & dosage*; D001549:Benzamides / Q000008:administration & dosage*; D003866:Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged; D020912:Moclobemide; D008996:Monoamine Oxidase Inhibitors / Q000008:administration & dosage*; D011569:Psychiatric Status Rating Scales
D000928:Antidepressive Agents; D001549:Benzamides; D008996:Monoamine Oxidase Inhibitors; D020912:Moclobemide